Sarepta Therapeutics Inc (SRPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has a cash flow conversion efficiency ratio of -0.004x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.61 Million) by net assets ($1.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sarepta Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sarepta Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sarepta Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sarepta Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Sarepta Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BWP Trust
AU:BWP
|
0.020x |
|
Interface Inc
NASDAQ:TILE
|
0.057x |
|
Changshu Tianyin Electromechan
SHE:300342
|
0.028x |
|
UIE PLC
CO:UIE
|
0.044x |
|
Super Retail Group Ltd
AU:SUL
|
0.298x |
|
Werner Enterprises Inc
NASDAQ:WERN
|
0.060x |
|
IQM Quantum Computers Oyj American Depositary Shares
NASDAQ:IQMX
|
-0.120x |
|
Dermapharm Holding SE
XETRA:DMP
|
0.054x |
Annual Cash Flow Conversion Efficiency for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Sarepta Therapeutics Inc from 1995 to 2025. View Sarepta Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.14 Billion | $-205.48 Million | -0.180x | -33.74% |
| 2024-12-31 | $1.53 Billion | $-205.79 Million | -0.135x | +76.90% |
| 2023-12-31 | $859.34 Million | $-500.99 Million | -0.583x | +31.02% |
| 2022-12-31 | $384.95 Million | $-325.35 Million | -0.845x | -76.98% |
| 2021-12-31 | $928.01 Million | $-443.17 Million | -0.478x | -438.51% |
| 2020-12-31 | $761.76 Million | $107.47 Million | 0.141x | +125.29% |
| 2019-12-31 | $818.19 Million | $-456.46 Million | -0.558x | -48.18% |
| 2018-12-31 | $1.03 Billion | $-388.66 Million | -0.377x | -28.08% |
| 2017-12-31 | $789.22 Million | $-232.00 Million | -0.294x | +59.74% |
| 2016-12-31 | $336.69 Million | $-245.82 Million | -0.730x | +7.02% |
| 2015-12-31 | $190.35 Million | $-149.47 Million | -0.785x | -51.29% |
| 2014-12-31 | $247.65 Million | $-128.54 Million | -0.519x | -98.31% |
| 2013-12-31 | $247.19 Million | $-64.69 Million | -0.262x | -9.01% |
| 2012-12-31 | $123.68 Million | $-29.69 Million | -0.240x | +68.55% |
| 2011-12-31 | $31.02 Million | $-23.68 Million | -0.763x | -114.14% |
| 2010-12-31 | $-2.82 Million | $-15.21 Million | 5.399x | +1549.76% |
| 2009-12-31 | $23.63 Million | $-8.80 Million | -0.372x | +52.52% |
| 2008-12-31 | $15.73 Million | $-12.34 Million | -0.784x | +16.15% |
| 2007-12-31 | $26.38 Million | $-24.68 Million | -0.935x | -71.13% |
| 2006-12-31 | $37.71 Million | $-20.61 Million | -0.547x | -99.95% |
| 2005-12-31 | $53.66 Million | $-14.67 Million | -0.273x | +69.80% |
| 2004-12-31 | $26.27 Million | $-23.78 Million | -0.905x | -124.74% |
| 2003-12-31 | $43.39 Million | $-17.48 Million | -0.403x | +53.32% |
| 2002-12-31 | $23.48 Million | $-20.26 Million | -0.863x | -105.49% |
| 2001-12-31 | $30.53 Million | $-12.82 Million | -0.420x | -53.48% |
| 2000-12-31 | $33.37 Million | $-9.13 Million | -0.274x | +57.16% |
| 1999-12-31 | $11.90 Million | $-7.60 Million | -0.639x | +14.21% |
| 1998-12-31 | $9.00 Million | $-6.70 Million | -0.744x | -354.11% |
| 1997-12-31 | $18.30 Million | $-3.00 Million | -0.164x | +91.80% |
| 1996-12-31 | $800.00K | $-1.60 Million | -2.000x | -124.72% |
| 1995-12-31 | $2.00 Million | $-1.78 Million | -0.890x | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more